Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.0K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.0K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

376
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
376
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

1.0K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.0K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

768
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
768
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[German S1 Guideline Long-/Post-COVID].

Pneumologie (Stuttgart, Germany)·2022
Same author

Ultrastructural analysis of explanted CyPass microstents and correlation with clinical findings.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2022
Same author

[Treatment-resistant nodular scleritis].

Die Ophthalmologie·2022
Same author

[Clinical and sonographic examination findings in patients with carotid-cavernous sinus fistulas].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2021
Same author

[Trabecular micro-invasive glaucoma surgery : Procedures and clinical results].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2018
Same author

[Retinal dystrophy with kidney disease].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2017
Same journal

["DOG 2020 online" - for the first time in the von Graefe year].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2024
Same journal

[Are organ and co-cultures an alternative to animal models in ophthalmology?]

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Pediatric corneal opacities : Even small improvements provide lifelong help].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Myxoma of the conjunctiva].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Secondary open-angle glaucoma: uveitic secondary glaucoma, steroid-induced glaucoma, posttraumatic and postoperative glaucoma, tumor-related glaucoma and glaucoma due to elevated episcleral venous pressure].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Artificial intelligence in the management of anti-VEGF treatment: the Vienna fluid monitor in clinical practice].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
See all related articles

Related Experiment Video

Updated: Feb 25, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.2K

[Zoledronate-induced panuveitis].

A Bergua1, B Hohberger2

  • 1Augenklinik am Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Deutschland. antonio.bergua@uk-erlangen.de.

Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|July 28, 2017
PubMed
Summary
This summary is machine-generated.

Zoledronate (Aclasta®) can cause rare uveitis, an eye inflammation. This report details a patient

Keywords:
BisphosphonateIatrogen inducedPanuveitisUveitisZoledronate

More Related Videos

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

28.4K
Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
11:47

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

Published on: March 4, 2022

2.7K

Related Experiment Videos

Last Updated: Feb 25, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.2K
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

28.4K
Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
11:47

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

Published on: March 4, 2022

2.7K

Area of Science:

  • Ophthalmology
  • Pharmacovigilance

Background:

  • Zoledronate (Aclasta®) is a bisphosphonate used to treat osteoporosis and bone metastases.
  • Uveitis is a rare but serious potential side effect of zoledronate therapy.
  • Ocular inflammation can lead to significant visual impairment.

Observation:

  • A case report of a female patient experiencing zoledronate-induced panuveitis.
  • Detailed clinical course, diagnostic procedures, and therapeutic interventions were documented.
  • The patient presented with inflammation affecting multiple parts of the uvea.

Findings:

  • Zoledronate-induced uveitis is a rare iatrogenic condition.
  • Panuveitis can manifest as a complication of zoledronate treatment.
  • Prompt diagnosis and management are crucial for visual outcomes.

Implications:

  • Highlights the importance of recognizing zoledronate-induced uveitis in clinical practice.
  • Emphasizes the need for ophthalmological evaluation in patients on zoledronate presenting with ocular symptoms.
  • Contributes to understanding the spectrum of adverse drug reactions associated with bisphosphonates.